OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
FDA Grants Orphan Drug Designation to Prestige BioPharma’s Anti-Cancer mAb
While there currently is no molecular therapy targeted against the PAUFgene, Prestige believes its monoclonal antibody has the potential to benefit patients affected by PAUF-positive pancreatic cancer.
Prestige BioPharma, a Singapore-based biopharmaceutical company, announced on June 30, 2020 that FDA has given orphan drug designation (ODD) to its first-in-class anti-pancreatic adenocarcinoma up-regulated factor (PAUF) monoclonal antibody (mAb), PBP1510, for the treatment of pancreatic cancer.
According to a company press release, the rapid expression of pancreatic cancer can be partially pinpointed to the PAUF gene. While there isn’t currently a molecular therapy targeted against PAUF, Prestige believes its mAb has the potential to benefit patients affected by PAUF-positive pancreatic cancer.
“The [o]rphan [d]rug [d]esignation we received from [FDA] is of significant importance in accelerating the development of PBP1510 to provide better treatment for pancreatic cancer, an extremely difficult to treat indication with a poor response to the currently available treatments,” said Dr. Lisa S. Park, CEO of Prestige BioPharma, in the press release.
Source: Prestige
